Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

NCT06655740 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether a procedure called duodenal mucosal RF vapor ablation is safe and well-tolerated in adults with type 2 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 16 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2024-10 · est. completion 2027-07

Where 1 site · Chile

What this study is testing ClinicalTrials.gov NCT06655740 ↗

Description as written by the study sponsor.

The purpose of this study is to determine whether RFVA of the duodenal mucosa with or without the combination of Semaglutide is a safe and effective treatment to remove the need for insulin therapy among patients with T2D who are on stable doses of insulin.

Treatments tested

RF Vapor Ablation Device

RF Vapor ablation of the duodenum

Main thing measured	Safety Endpoint
Sponsor	Aqua Medical, Inc.
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06655740 ↗